XTX Topco Ltd Buys New Position in Protara Therapeutics, Inc. (NASDAQ:TARA)

XTX Topco Ltd bought a new position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 32,682 shares of the company’s stock, valued at approximately $60,000. XTX Topco Ltd owned approximately 0.16% of Protara Therapeutics as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of TARA. Armistice Capital LLC purchased a new position in Protara Therapeutics in the second quarter worth approximately $1,082,000. CVI Holdings LLC acquired a new stake in shares of Protara Therapeutics in the 2nd quarter valued at $630,000. Oppenheimer & Co. Inc. lifted its position in shares of Protara Therapeutics by 40.8% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 179,125 shares of the company’s stock worth $328,000 after purchasing an additional 51,944 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Protara Therapeutics by 77.8% during the second quarter. Renaissance Technologies LLC now owns 150,400 shares of the company’s stock worth $313,000 after purchasing an additional 65,800 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Protara Therapeutics during the second quarter worth $161,000. Institutional investors and hedge funds own 38.13% of the company’s stock.

Analyst Upgrades and Downgrades

TARA has been the subject of several analyst reports. Guggenheim reaffirmed a “buy” rating and set a $20.00 price objective on shares of Protara Therapeutics in a research report on Friday, December 6th. HC Wainwright restated a “buy” rating and issued a $23.00 target price on shares of Protara Therapeutics in a report on Friday, December 6th.

Protara Therapeutics Stock Up 4.1 %

TARA opened at $5.39 on Monday. Protara Therapeutics, Inc. has a 52 week low of $1.60 and a 52 week high of $10.48. The business’s 50 day moving average is $3.25 and its two-hundred day moving average is $2.50. The firm has a market cap of $111.20 million, a price-to-earnings ratio of -1.91 and a beta of 1.78.

Protara Therapeutics (NASDAQ:TARA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.50) EPS for the quarter, meeting analysts’ consensus estimates of ($0.50). Equities analysts expect that Protara Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.